ArticleEuropean journal of nuclear medicine and molecular imaging2026
High-contrast somatostatin receptor imaging of meningiomas with [¹⁸F]SiTATE PET/CT.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSomatostatin receptor (SSTR)-targeted PET imaging is increasingly used in the management of meningiomas. While gallium-68-labeled tracers are widely used, fluorine-18-labeled compounds may offer logistical and imaging advantages. We evaluated the feasibility and imaging characteristics of the novel SSTR ligand [¹⁸F]SiTATE PET/CT in patients with suspected or known meningioma.
methodsThirty-seven consecutive patients undergoing [¹⁸F]SiTATE PET/CT for suspected or known meningioma were retrospectively analyzed. Lesion detectability, tracer uptake, and tumor-to-background contrast were assessed. Semiquantitative parameters including SUVmax, SUVpeak, somatostatin receptor-expressing tumor volume (SRETV), and total lesion somatostatin receptor expression (TLSRE) were calculated. PET findings were verified by histopathology when available and otherwise by MRI follow-up as part of a composite reference standard.
resultsFocal tracer uptake consistent with meningioma was observed in 32/37 examinations (86.5%), identifying 69 lesions in total. Meningiomas demonstrated intense uptake (SUVmax 20.44 ± 14.54; SUVpeak 12.10 ± 8.04), significantly higher than non-meningioma lesions and reference tissues (all p < 0.01 except pituitary gland). Physiological uptake in normal brain parenchyma was minimal (SUVmax 0.11 ± 0.06), resulting in excellent tumor-to-background contrast. Mean SRETV and TLSRE were 9.81 ± 13.64 mL and 102.86 ± 193.69, respectively. No tracer-related adverse events occurred.
conclusionIn this retrospective cohort, [¹⁸F]SiTATE PET/CT enabled high-contrast visualization of meningiomas with intense tumor uptake and minimal background activity. These findings support the feasibility of [¹⁸F]SiTATE as an ¹⁸F-labeled SSTR tracer for meningioma imaging and justify prospective comparative evaluation.
Indexed as
Identifiers
42665702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.